We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC Issues Second Request To Watson, Andrx

Law360 (May 3, 2006, 12:00 AM EDT) -- The proposed marriage of generic drug makers Watson Pharmaceuticals Inc. and Andrx Corp. has drawn new attention from the Federal Trade Commission, which issued a second request for information in order to study possible antitrust concerns.

The agency has plenty of details to crunch, given the multiple overlapping drugs manufactured by the companies, which hope to merge after Watson announced in March its plans to purchase Andrx for $1.9 billion.

Although only about 3% of proposed corporate mergers lead to second requests for information from the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.